BNR:NSD-Burning Rock Biotech Limited (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 20.41

Change

0.00 (0.00)%

Market Cap

USD 2.13B

Volume

1.15M

Avg Analyst Target

USD 39.94 (+95.69%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China. Address: Building 3, Standard Industrial Unit 2, Guangzhou, China, 510005

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina Inc

N/A

USD69.96B 85.60 59.78
IDXX IDEXX Laboratories Inc

N/A

USD56.30B 78.89 59.20
DXCM DexCom Inc

N/A

USD54.48B 105.50 123.24
ICLR ICON Public Limited Company

N/A

USD21.37B 39.11 38.54
EXAS Exact Sciences Corporation

N/A

USD18.60B N/A N/A
GH Guardant Health Inc

N/A

USD12.86B N/A N/A
NTRA Natera Inc

N/A

USD11.85B N/A N/A
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
SYNH Syneos Health Inc

N/A

USD9.75B 42.03 22.23
MEDP Medpace Holdings Inc

N/A

USD6.66B 40.10 29.18

ETFs Containing BNR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.65% 31% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.65% 31% F 25% F
Trailing 12 Months  
Capital Gain -10.13% 29% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.13% 29% F 17% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.51% 25% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.51% 23% F 18% F
Risk Return Profile  
Volatility (Standard Deviation) 3.98% 98% A+ 97% A+
Risk Adjusted Return -12.92% 18% F 14% F
Market Capitalization 2.13B 67% D+ 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 97% A+ 96% A
Price/Book Ratio 6.08 37% F 24% F
Price / Cash Flow Ratio -29.01 84% B 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -27.13% 55% F 37% F
Return on Invested Capital -50.62% 36% F 16% F
Return on Assets -14.91% 41% F 23% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.44 48% F 31% F
Short Percent 3.69% 67% D+ 43% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector